Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Avenue Therapeutics Inc
ATXI | US
0.22
USD0.04
24.22%
ATXI | US
About Avenue Therapeutics Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
06/03/2026
Close
0.22
Open
0.18
High
0.22
Low
0.18
Avenue Therapeutics Inc. a specialty pharmaceutical company develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201 which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics Inc. was incorporated in 2015 and is based in Tampa Florida.
View LessATXI | US
Risk
314.1
Sharpe
-0.39
Luna's Score
42/100
Recommendation
Sell
Luna says (ATXI | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
395.9%1 month
314.1%3 months
194.7%6 months
164.8%Returns
Fundamental Ratios
PE
0.06
Fwd. PE
17.99
Price to book
0.63
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-0.42
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
314.90K
MarketCap(USD)
314.90K
Div. yield
-
Op. margin
-
Erngs. growth
-76.30
Rev. growth
-
Ret. on equity
-535.10
Short ratio
1.14
Short perc.
2.20
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.15
Range1M
0.15
Range3M
0.65
Volumes: Market Activity
Rel. volume
0.11
Price X volume
165.66
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.42 | 24.85 | Cheaper |
| Ent. to Revenue | - | 361.91 | - |
| PE Ratio | 0.06 | 30.05 | Cheaper |
| Price to Book | 0.63 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 194.67 | 65.24 | Riskier |
| Debt to Equity | - | -1.88 | - |
| Debt to Assets | - | 0.48 | - |
| Market Cap | 314.90K | 3.71B | Emerging |
